919 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
TEVA Teva Pharmaceutical Industries Limited $23.43 $23.86B N/A
Article Searches
FDA accepts Teva's sNDA for expanded label for ProAir RespiClick http://seekingalpha.com/news/2771396-fda-accepts-tevas-snda-for-expanded-label-for-proair-respiclick?source=feed_news_all Sep 10, 2015 - The FDA accepts for review the supplemental New Drug Application (sNDA) from Teva Pharmaceutical Industries ([[TEVA]] -0.3%) seeking approval for the use o
IBM Watson Health and Teva Pharma team up in Health Cloud http://seekingalpha.com/news/2770806-ibm-watson-health-and-teva-pharma-team-up-in-health-cloud?source=feed_news_all Sep 10, 2015 - IBM Watson Health announces that Teva Pharmaceutical Industries (TEVA) is the first global pharma firm to sign on as a Foundational Life Sciences Partner f
Menta increased its stake in Teva by 41% http://www.gurufocus.com/news/359864/hedge-fund-menta-capitals-top-stocks-include-teva-pharmaceutical-nice-systems- Sep 09, 2015 - Hedge Fund Menta Capital's Top Stocks Include Teva Pharmaceutical, NICE Systems, Stocks: TEVA,NICE,MLNX, George Soros,John Paulson, release date:Sep 09, 2015
Eli Lilly's Alimta Patent Upheld by U.S. District Court http://www.zacks.com/stock/news/187860/eli-lillys-alimta-patent-upheld-by-us-district-court?cid=CS-ZC-FT-187860 Aug 26, 2015 - Eli Lilly and Company announced that it has received a favorable ruling in a lawsuit related to the infringement of vitamin regimen patent for Alimta.
Acorda (ACOR) Gets Favorable Outcome in Ampyra IPR Issue http://www.zacks.com/stock/news/187680/acorda-acor-gets-favorable-outcome-in-ampyra-ipr-issue?cid=CS-ZC-FT-187680 Aug 25, 2015 - Acorda (ACOR) received encouraging news with the patent review board refusing to review two patents related to Ampyra.
Teva's Phase III Rejig Leaves Some Unanswered Questions http://seekingalpha.com/article/3465286-tevas-phase-iii-rejig-leaves-some-unanswered-questions?source=feed_tag_israel Aug 25, 2015 - The changes disclosed last week to Teva’s (NYSE:TEVA) phase III trial with the Mesoblast-licensed CEP-41750/rexlemestrocel-L stem cell therapy in chronic heart failure are ostensibly designed t
Teva's Acquisition Program A Winner http://seekingalpha.com/article/3464246-tevas-acquisition-program-a-winner?source=feed_tag_israel Aug 25, 2015 - Despite Capaxone worries, Teva is growing organically, and its fundamental strengths continue to be evident in quarterly reports.
Novartis to Buy Full Arzerra Rights from GlaxoSmithKline http://www.zacks.com/stock/news/187507/novartis-to-buy-full-arzerra-rights-from-glaxosmithkline?cid=CS-ZC-FT-187507 Aug 24, 2015 - Novartis (NVS) inked a deal with GlaxoSmithKline to acquire all remaining rights to Arzerra for up to $1 billion plus royalties.
China Tanks as Q2 Marches On http://www.zacks.com/stock/news/183388/china-tanks-as-q2-marches-on?cid=CS-ZC-FT-183388 Jul 27, 2015 - Questions about the sustainability of Chinese government funds' ability to stabilize the market cause a pullback in market support. As a result, the Shanghai index dropped 8.5 percent and the Shenzhen was down 7 percent.

Pages: 1...878889909192

<<<Page 92